Research Analysts Offer Predictions for Merck & Co., Inc.’s Q1 2022 Earnings (NYSE:MRK)

Merck & Co., Inc. (NYSE:MRKGet Rating) – SVB Leerink dropped their Q1 2022 earnings estimates for shares of Merck & Co., Inc. in a report released on Thursday, April 21st. SVB Leerink analyst D. Graybosch now expects that the company will post earnings of $1.72 per share for the quarter, down from their previous estimate of $1.89. SVB Leerink currently has a “Outperform” rating and a $97.00 price target on the stock. SVB Leerink also issued estimates for Merck & Co., Inc.’s Q1 2023 earnings at $1.71 EPS, Q2 2023 earnings at $1.75 EPS, Q3 2023 earnings at $1.79 EPS and Q4 2023 earnings at $1.88 EPS.

Several other equities research analysts have also issued reports on MRK. Morgan Stanley lowered their price objective on Merck & Co., Inc. from $82.00 to $80.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 6th. Barclays raised their price objective on Merck & Co., Inc. from $94.00 to $97.00 and gave the company an “overweight” rating in a research note on Tuesday, April 12th. JPMorgan Chase & Co. lowered their price objective on Merck & Co., Inc. from $100.00 to $95.00 and set an “overweight” rating for the company in a research note on Friday, January 28th. Mizuho began coverage on Merck & Co., Inc. in a research note on Friday, April 1st. They issued a “buy” rating and a $100.00 price objective for the company. Finally, StockNews.com began coverage on Merck & Co., Inc. in a research note on Thursday, March 31st. They set a “strong-buy” rating for the company. Eight investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Merck & Co., Inc. has a consensus rating of “Buy” and an average price target of $90.69.

NYSE:MRK opened at $84.59 on Friday. The company has a current ratio of 1.27, a quick ratio of 1.02 and a debt-to-equity ratio of 0.80. Merck & Co., Inc. has a 12-month low of $70.89 and a 12-month high of $91.40. The stock has a 50-day moving average price of $80.58 and a 200 day moving average price of $79.90. The stock has a market capitalization of $213.83 billion, a P/E ratio of 16.46, a P/E/G ratio of 1.41 and a beta of 0.45.

Merck & Co., Inc. (NYSE:MRKGet Rating) last posted its earnings results on Thursday, February 3rd. The company reported $1.80 earnings per share for the quarter, beating analysts’ consensus estimates of $1.46 by $0.34. Merck & Co., Inc. had a return on equity of 47.24% and a net margin of 26.02%. The company had revenue of $13.25 billion for the quarter, compared to the consensus estimate of $13.14 billion. During the same quarter in the prior year, the company earned $1.32 earnings per share. Merck & Co., Inc.’s revenue was up 5.9% on a year-over-year basis.

A number of hedge funds have recently made changes to their positions in MRK. Kovitz Investment Group Partners LLC grew its stake in Merck & Co., Inc. by 12.5% during the 1st quarter. Kovitz Investment Group Partners LLC now owns 104,782 shares of the company’s stock valued at $8,597,000 after purchasing an additional 11,622 shares during the last quarter. Allworth Financial LP grew its stake in Merck & Co., Inc. by 20.0% during the 1st quarter. Allworth Financial LP now owns 30,507 shares of the company’s stock valued at $2,503,000 after purchasing an additional 5,080 shares during the last quarter. Bank of The West lifted its holdings in shares of Merck & Co., Inc. by 4.2% in the 1st quarter. Bank of The West now owns 114,723 shares of the company’s stock valued at $9,413,000 after buying an additional 4,643 shares during the period. Truist Financial Corp lifted its holdings in shares of Merck & Co., Inc. by 1.6% in the 1st quarter. Truist Financial Corp now owns 5,202,869 shares of the company’s stock valued at $426,896,000 after buying an additional 83,517 shares during the period. Finally, UMB Bank N A MO lifted its holdings in shares of Merck & Co., Inc. by 1.2% in the 1st quarter. UMB Bank N A MO now owns 238,963 shares of the company’s stock valued at $19,607,000 after buying an additional 2,861 shares during the period. Hedge funds and other institutional investors own 72.05% of the company’s stock.

The firm also recently announced a quarterly dividend, which was paid on Thursday, April 7th. Investors of record on Tuesday, March 15th were paid a dividend of $0.69 per share. The ex-dividend date was Monday, March 14th. This represents a $2.76 annualized dividend and a yield of 3.26%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 53.70%.

Merck & Co., Inc. Company Profile (Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Further Reading

Earnings History and Estimates for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.